Entity

Time filter

Source Type

Nishi-Tokyo-shi, Japan

The present invention has an object to provide an insoluble carrier for an antiphospholipid antibody detection reagent having a high reactivity. The present invention also has an object to provide an antiphospholipid antibody detection reagent, and a method of detecting an antiphospholipid antibody. The present invention directs to an insoluble carrier for an antiphospholipid antibody detection reagent, having a zeta potential of lower than 45 mV in the case that the insoluble carrier is suspended in a 20 mmol/L aqueous sodium phosphate solution with a pH of 7.4 so that the resulting suspension has a solids concentration of 0.1%.


Provided is a sample injection device for flow-type analysis including a cylindrical needle (


Patent
Sekisui Medical Co. | Date: 2015-09-25

Provided is a method for the simple and highly accurate assay of PSA by a one-step reaction that does not use carriers having different average grain sizes. Also provided is a reagent therefor. The PSA assay method comprises sensitizing insoluble carriers having the same average grain size within a range of greater than 0.20 nm but 0.40 nm or less using two types of anti-PSA monoclonal antibodies having different epitopes that are anti-PSA monoclonal antibodies that will react with both free PSA and PSA-ACT, which is a complex of free PSA and 1-antichymotrypsin, and bringing the carriers into contact with a sample in the presence of an aggregation promoter.


Patent
Sekisui Medical Co. | Date: 2015-08-05

Provided is a general-purpose technique capable of measuring the HbA1c content, which is comparable to the IFCC reference method. An antibody which reacts with a peptide or a protein having an amino acid sequence of VHLTPE (SEQ ID NO: 1) at the N-terminus in which the N-terminal valine is not modified, but does not react with a peptide or a protein in which the N-terminal valine of the relevant polypeptide or protein is modified.


Patent
Sekisui Medical Co. | Date: 2015-03-12

A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells. The present invention ensures convenient and accurate evaluation of human CYP3A inducibility upon administration of a test drug to a human subject, providing accurate evaluation in terms of the efficacy of the test drug, occurrence of side effects, disappearance of the drug effect, etc.

Discover hidden collaborations